Reszke Radomir, Krajewski Piotr, Szepietowski Jacek C
Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, 1 Chalubinskiego Street, 50-368, Wrocław, Poland.
Am J Clin Dermatol. 2020 Oct;21(5):601-618. doi: 10.1007/s40257-020-00534-y.
Chronic pruritus, defined as an unpleasant sensation resulting in a need to scratch that lasts more than 6 weeks, is a prevalent and bothersome symptom associated with both cutaneous and systemic conditions. Due to complex pathogenesis and profuse contributing factors, chronic pruritus therapy remains challenging. Regardless of the well-established antipruritic properties of classic pharmacotherapy (topical therapy, phototherapy and systemic therapy), these methods often provide insufficient relief for affected individuals. Owing to the growing interest in the field of pruritic research, further experimental and clinical data have emerged, continuously supporting the possibility of instigating novel therapeutic measures. This review covers the most relevant current modalities remaining under investigation that possess promising perspectives of approval in the near future, especially opioidergic drugs (mu-opioid antagonists and kappa-opioid agonists), neurokinin-1 receptor antagonists, biologic drugs, Janus kinase inhibitors, ileal bile acid transporter inhibitors, aryl hydrocarbon receptor agonists and histamine H receptor antagonists.
慢性瘙痒被定义为一种令人不适的感觉,导致需要搔抓且持续超过6周,是一种与皮肤和全身性疾病相关的普遍且烦人的症状。由于发病机制复杂且促成因素众多,慢性瘙痒的治疗仍然具有挑战性。尽管经典药物疗法(局部治疗、光疗和全身治疗)具有公认的止痒特性,但这些方法往往无法为受影响的个体提供足够的缓解。由于对瘙痒研究领域的兴趣日益浓厚,更多的实验和临床数据不断涌现,持续支持采取新治疗措施的可能性。本综述涵盖了目前仍在研究的最相关的治疗方式,这些方式在不久的将来具有有望获批的前景,特别是阿片类药物(μ-阿片受体拮抗剂和κ-阿片受体激动剂)、神经激肽-1受体拮抗剂、生物药物、Janus激酶抑制剂、回肠胆汁酸转运体抑制剂、芳烃受体激动剂和组胺H受体拮抗剂。